{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:27:23Z","timestamp":1793114843706,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ijantimicag.2023.106830","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T11:25:23Z","timestamp":1682335523000},"page":"106830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"62","author":[{"given":"Kuo-Chuan","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-5989","authenticated-orcid":false,"given":"Chin-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106830_bib0001","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOU.0000000000000364","article-title":"An update on classification and management of urosepsis","volume":"27","author":"Wagenlehner","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0003","doi-asserted-by":"crossref","first-page":"e12694","DOI":"10.1002\/emp2.12694","article-title":"Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016\u20132018","volume":"3","author":"Zilberberg","year":"2022","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0004","doi-asserted-by":"crossref","first-page":"ofab591","DOI":"10.1093\/ofid\/ofab591","article-title":"Descriptive epidemiology and outcomes of hospitalizations with complicated urinary tract infections in the United States, 2018","volume":"9","author":"Zilberberg","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0005","doi-asserted-by":"crossref","first-page":"ofac315","DOI":"10.1093\/ofid\/ofac315","article-title":"Epidemiology of complicated urinary tract infections due to Enterobacterales among adult patients presenting in emergency departments across the United States","volume":"9","author":"Lodise","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0006","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jgar.2020.04.011","volume":"22","author":"Yang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106521","volume":"59","author":"Jean","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jac\/dkw398","volume":"72","author":"Jean","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0009","volume":"58","author":"Lee","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01089-20","article-title":"National surveillance of antimicrobial susceptibility of bacteremic Gram-negative bacteria with emphasis on community-acquired resistant isolates: report from the 2019 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)","volume":"64","author":"Liu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0011","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jgar.2021.02.004","article-title":"Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: a systematic review and meta-analysis of randomised controlled trials","volume":"24","author":"Hsueh","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0012","doi-asserted-by":"crossref","first-page":"e19960","DOI":"10.1097\/MD.0000000000019960","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: a meta-analysis of randomized controlled trials","volume":"99","author":"Lu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0013","doi-asserted-by":"crossref","first-page":"ofac429","DOI":"10.1093\/ofid\/ofac429","article-title":"Efficacy and safety of plazomicin in the treatment of enterobacterales infections: a meta-analysis of randomized controlled trials","volume":"9","author":"Yan","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02317-17","article-title":"Explorative randomized phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections","volume":"62","author":"Wagenlehner","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0016","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0017","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4097\/kja.20637","article-title":"Trial sequential analysis: plain and simple","volume":"74","author":"De Cassai","year":"2021","journal-title":"Korean J Anesthesiol"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0018","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/EJA.0000000000001539","article-title":"Efficacy and airway complications of Parker Flex-Tip tubes and standard endotracheal tubes during airway manipulation: a meta-analysis and trial sequential analysis","volume":"38","author":"Hung","year":"2021","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1017098","article-title":"General anesthesia but not conscious sedation improves functional outcome in patients receiving endovascular thrombectomy for acute ischemic stroke: a meta-analysis of randomized clinical trials and trial sequence analysis","volume":"13","author":"Lee","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0022","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0023","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0024","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0025","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0026","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0027","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0028","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0029","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.925662","article-title":"Efficacy and safety of novel carbapenem-\u03b2-lactamase inhibitor combinations: results from phase II and III trials","volume":"12","author":"Yu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.11.015","article-title":"The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections \u2013 meta-analysis of randomized controlled trials","volume":"55","author":"Cheng","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","year":"2019","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0033","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2217\/cer-2021-0138","article-title":"Antibacterial data synthesis challenges: a systematic review of treatments for complicated Gram-negative urinary tract infections","volume":"10","author":"Dillon","year":"2021","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0034","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a phase 3 clinical trial programme for the treatment of complicated urinary tract infections","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02712-21","article-title":"In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106830_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02068-18","article-title":"In vitro activity of plazomicin against Gram-negative and Gram-positive bacterial pathogens isolated from patients in Canadian hospitals from 2013 to 2017 as part of the CANWARD Surveillance Study","volume":"63","author":"Walkty","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:48:14Z","timestamp":1760377694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0924857923001097"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106830","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106830"}}